MYP_167532
Basic Information
Brentuximab vedotin
Anticancer
Standard
243 amino acids
C1170H1782N292O357S8
Standard
Sequence
QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLF
Physicochemical Analysis
25906.93 Da
8.74
4.95
4.43
0.0204
-0.17
0.53
0.13
34.58
66.54
0.1152
50880.00
51255.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0410033 VERIFIED: YES
Provenance & Taxonomy
Homo sapiens [Animal]
Antibody-drug conjugate
9606
Structure & Mods
linear multidomain protein biologic [Linear]
noncanonical stereochemical or chemical modification [Modified]
MMAE drug conjugation
Bio-Activity Profile
Anticancer Monoclonal antibody
Terminal half-life is 4-6 d